Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period
Summary Species level identification of Candida and antifungal susceptibility testing is not generally performed in routine laboratory practice. There is limited information about the distribution of Candida species and antifungal susceptibility in Turkey. In this study, we aimed at identifying Cand...
Gespeichert in:
| Veröffentlicht in: | Mycoses 2007-01, Vol.50 (1), p.52-57 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 57 |
|---|---|
| container_issue | 1 |
| container_start_page | 52 |
| container_title | Mycoses |
| container_volume | 50 |
| creator | Comert, Fusun Kulah, Canan Aktas, Elif Eroglu, Ozlem Ozlu, Nagihan |
| description | Summary
Species level identification of Candida and antifungal susceptibility testing is not generally performed in routine laboratory practice. There is limited information about the distribution of Candida species and antifungal susceptibility in Turkey. In this study, we aimed at identifying Candida isolates to species level from various samples obtained from patients treated in an intensive care unit between 2002 and 2005 and to evaluate fluconazole susceptibilities of the isolates. A total of 320 Candida isolates obtained from 270 patients were identified by conventional methods and using API (Candida and/or 20C AUX) system. Antifungal susceptibility testing was performed by broth microdilution method. Candida albicans was isolated with the highest frequency (65.6%) followed by C. parapsilosis (11.3%), C. glabrata (8.8%) and C. tropicalis (7.8%). Of all the isolates, 92.9% revealed susceptibility to fluconazole. Susceptibility to fluconazole was highest for C. albicans followed by C. parapsilosis and C. glabrata. The MIC90 values for C. albicans, C. parapsilosis, C. glabrata and C. tropicalis were 1, 2, 8 and 4 μg ml−1 respectively. Fluconazole remains effective against both C. albicans and the majority of non‐albicans Candida species. In this study, we determine the distribution of Candida species and evaluate the susceptibilities of the isolates, particularly for the azoles. |
| doi_str_mv | 10.1111/j.1439-0507.2006.01309.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69011157</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20467489</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4369-14795481675b47b2dfed4bb9975aeeeef6c687de6664f4a063c83e9fc866e4833</originalsourceid><addsrcrecordid>eNqNkUFvFCEYhonR2LX6FwwnbzMyAwPDwYPZaNtkq4e2MZ4Iw3wkrLPDCEzd7Y_wN5dxN_WohATC9z4fhAchXJGyyuP9tqwYlQVpiChrQnhJKkpkuX-GVk-F52hFJKWFYEScoVcxbgmphKz5S3RWCUpqweQK_b7qYUzOOqOT8yP2Fq_12Lte4ziBcRCxi37QCXpsg9_hKecykY_HPBOM0d0DNjoAnkeXcIaX0r1LweM4RwNTcp0bXDrg5LEdZuNH_eAHwNYHrDEtDqADniA4379GL6weIrw5refo7vOn2_Vlsfl6cbX-uCkMo1wWFROyYW3FRdMx0dW9hZ51nZSi0ZCH5Ya3ogfOObNME05NS0Fa03IOrKX0HL079p2C_zlDTGrn8lOHQY_g56i4JPmfG_HPYE0YF6yVOdgegyb4GANYNQW30-GgKqIWaWqrFjdqcaMWaeqPNLXP6NvTHXO3g_4veLKUAx-OgV9ugMN_N1bX39fLLvPFkXcxwf6J1-GH4oKKRn37cqFuLptbcc02qqaPoiO3AQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20467489</pqid></control><display><type>article</type><title>Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Comert, Fusun ; Kulah, Canan ; Aktas, Elif ; Eroglu, Ozlem ; Ozlu, Nagihan</creator><creatorcontrib>Comert, Fusun ; Kulah, Canan ; Aktas, Elif ; Eroglu, Ozlem ; Ozlu, Nagihan</creatorcontrib><description>Summary
Species level identification of Candida and antifungal susceptibility testing is not generally performed in routine laboratory practice. There is limited information about the distribution of Candida species and antifungal susceptibility in Turkey. In this study, we aimed at identifying Candida isolates to species level from various samples obtained from patients treated in an intensive care unit between 2002 and 2005 and to evaluate fluconazole susceptibilities of the isolates. A total of 320 Candida isolates obtained from 270 patients were identified by conventional methods and using API (Candida and/or 20C AUX) system. Antifungal susceptibility testing was performed by broth microdilution method. Candida albicans was isolated with the highest frequency (65.6%) followed by C. parapsilosis (11.3%), C. glabrata (8.8%) and C. tropicalis (7.8%). Of all the isolates, 92.9% revealed susceptibility to fluconazole. Susceptibility to fluconazole was highest for C. albicans followed by C. parapsilosis and C. glabrata. The MIC90 values for C. albicans, C. parapsilosis, C. glabrata and C. tropicalis were 1, 2, 8 and 4 μg ml−1 respectively. Fluconazole remains effective against both C. albicans and the majority of non‐albicans Candida species. In this study, we determine the distribution of Candida species and evaluate the susceptibilities of the isolates, particularly for the azoles.</description><identifier>ISSN: 0933-7407</identifier><identifier>EISSN: 1439-0507</identifier><identifier>DOI: 10.1111/j.1439-0507.2006.01309.x</identifier><identifier>PMID: 17302749</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Antifungal Agents - pharmacology ; Candida - classification ; Candida - drug effects ; Candida - isolation & purification ; Candida albicans ; Candida species ; Candidiasis - microbiology ; Female ; Fluconazole - pharmacology ; fluconazole susceptibility ; Hospitals, University ; Humans ; Intensive Care Units ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Turkey</subject><ispartof>Mycoses, 2007-01, Vol.50 (1), p.52-57</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4369-14795481675b47b2dfed4bb9975aeeeef6c687de6664f4a063c83e9fc866e4833</citedby><cites>FETCH-LOGICAL-c4369-14795481675b47b2dfed4bb9975aeeeef6c687de6664f4a063c83e9fc866e4833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1439-0507.2006.01309.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1439-0507.2006.01309.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17302749$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Comert, Fusun</creatorcontrib><creatorcontrib>Kulah, Canan</creatorcontrib><creatorcontrib>Aktas, Elif</creatorcontrib><creatorcontrib>Eroglu, Ozlem</creatorcontrib><creatorcontrib>Ozlu, Nagihan</creatorcontrib><title>Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period</title><title>Mycoses</title><addtitle>Mycoses</addtitle><description>Summary
Species level identification of Candida and antifungal susceptibility testing is not generally performed in routine laboratory practice. There is limited information about the distribution of Candida species and antifungal susceptibility in Turkey. In this study, we aimed at identifying Candida isolates to species level from various samples obtained from patients treated in an intensive care unit between 2002 and 2005 and to evaluate fluconazole susceptibilities of the isolates. A total of 320 Candida isolates obtained from 270 patients were identified by conventional methods and using API (Candida and/or 20C AUX) system. Antifungal susceptibility testing was performed by broth microdilution method. Candida albicans was isolated with the highest frequency (65.6%) followed by C. parapsilosis (11.3%), C. glabrata (8.8%) and C. tropicalis (7.8%). Of all the isolates, 92.9% revealed susceptibility to fluconazole. Susceptibility to fluconazole was highest for C. albicans followed by C. parapsilosis and C. glabrata. The MIC90 values for C. albicans, C. parapsilosis, C. glabrata and C. tropicalis were 1, 2, 8 and 4 μg ml−1 respectively. Fluconazole remains effective against both C. albicans and the majority of non‐albicans Candida species. In this study, we determine the distribution of Candida species and evaluate the susceptibilities of the isolates, particularly for the azoles.</description><subject>Adult</subject><subject>Aged</subject><subject>Antifungal Agents - pharmacology</subject><subject>Candida - classification</subject><subject>Candida - drug effects</subject><subject>Candida - isolation & purification</subject><subject>Candida albicans</subject><subject>Candida species</subject><subject>Candidiasis - microbiology</subject><subject>Female</subject><subject>Fluconazole - pharmacology</subject><subject>fluconazole susceptibility</subject><subject>Hospitals, University</subject><subject>Humans</subject><subject>Intensive Care Units</subject><subject>Male</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Turkey</subject><issn>0933-7407</issn><issn>1439-0507</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUFvFCEYhonR2LX6FwwnbzMyAwPDwYPZaNtkq4e2MZ4Iw3wkrLPDCEzd7Y_wN5dxN_WohATC9z4fhAchXJGyyuP9tqwYlQVpiChrQnhJKkpkuX-GVk-F52hFJKWFYEScoVcxbgmphKz5S3RWCUpqweQK_b7qYUzOOqOT8yP2Fq_12Lte4ziBcRCxi37QCXpsg9_hKecykY_HPBOM0d0DNjoAnkeXcIaX0r1LweM4RwNTcp0bXDrg5LEdZuNH_eAHwNYHrDEtDqADniA4379GL6weIrw5refo7vOn2_Vlsfl6cbX-uCkMo1wWFROyYW3FRdMx0dW9hZ51nZSi0ZCH5Ya3ogfOObNME05NS0Fa03IOrKX0HL079p2C_zlDTGrn8lOHQY_g56i4JPmfG_HPYE0YF6yVOdgegyb4GANYNQW30-GgKqIWaWqrFjdqcaMWaeqPNLXP6NvTHXO3g_4veLKUAx-OgV9ugMN_N1bX39fLLvPFkXcxwf6J1-GH4oKKRn37cqFuLptbcc02qqaPoiO3AQ</recordid><startdate>200701</startdate><enddate>200701</enddate><creator>Comert, Fusun</creator><creator>Kulah, Canan</creator><creator>Aktas, Elif</creator><creator>Eroglu, Ozlem</creator><creator>Ozlu, Nagihan</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>200701</creationdate><title>Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period</title><author>Comert, Fusun ; Kulah, Canan ; Aktas, Elif ; Eroglu, Ozlem ; Ozlu, Nagihan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4369-14795481675b47b2dfed4bb9975aeeeef6c687de6664f4a063c83e9fc866e4833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antifungal Agents - pharmacology</topic><topic>Candida - classification</topic><topic>Candida - drug effects</topic><topic>Candida - isolation & purification</topic><topic>Candida albicans</topic><topic>Candida species</topic><topic>Candidiasis - microbiology</topic><topic>Female</topic><topic>Fluconazole - pharmacology</topic><topic>fluconazole susceptibility</topic><topic>Hospitals, University</topic><topic>Humans</topic><topic>Intensive Care Units</topic><topic>Male</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Turkey</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Comert, Fusun</creatorcontrib><creatorcontrib>Kulah, Canan</creatorcontrib><creatorcontrib>Aktas, Elif</creatorcontrib><creatorcontrib>Eroglu, Ozlem</creatorcontrib><creatorcontrib>Ozlu, Nagihan</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Mycoses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Comert, Fusun</au><au>Kulah, Canan</au><au>Aktas, Elif</au><au>Eroglu, Ozlem</au><au>Ozlu, Nagihan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period</atitle><jtitle>Mycoses</jtitle><addtitle>Mycoses</addtitle><date>2007-01</date><risdate>2007</risdate><volume>50</volume><issue>1</issue><spage>52</spage><epage>57</epage><pages>52-57</pages><issn>0933-7407</issn><eissn>1439-0507</eissn><abstract>Summary
Species level identification of Candida and antifungal susceptibility testing is not generally performed in routine laboratory practice. There is limited information about the distribution of Candida species and antifungal susceptibility in Turkey. In this study, we aimed at identifying Candida isolates to species level from various samples obtained from patients treated in an intensive care unit between 2002 and 2005 and to evaluate fluconazole susceptibilities of the isolates. A total of 320 Candida isolates obtained from 270 patients were identified by conventional methods and using API (Candida and/or 20C AUX) system. Antifungal susceptibility testing was performed by broth microdilution method. Candida albicans was isolated with the highest frequency (65.6%) followed by C. parapsilosis (11.3%), C. glabrata (8.8%) and C. tropicalis (7.8%). Of all the isolates, 92.9% revealed susceptibility to fluconazole. Susceptibility to fluconazole was highest for C. albicans followed by C. parapsilosis and C. glabrata. The MIC90 values for C. albicans, C. parapsilosis, C. glabrata and C. tropicalis were 1, 2, 8 and 4 μg ml−1 respectively. Fluconazole remains effective against both C. albicans and the majority of non‐albicans Candida species. In this study, we determine the distribution of Candida species and evaluate the susceptibilities of the isolates, particularly for the azoles.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17302749</pmid><doi>10.1111/j.1439-0507.2006.01309.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0933-7407 |
| ispartof | Mycoses, 2007-01, Vol.50 (1), p.52-57 |
| issn | 0933-7407 1439-0507 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69011157 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Aged Antifungal Agents - pharmacology Candida - classification Candida - drug effects Candida - isolation & purification Candida albicans Candida species Candidiasis - microbiology Female Fluconazole - pharmacology fluconazole susceptibility Hospitals, University Humans Intensive Care Units Male Microbial Sensitivity Tests Middle Aged Turkey |
| title | Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T22%3A40%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20Candida%20species%20isolated%20from%20patients%20in%20intensive%20care%20unit%20and%20in%20vitro%20susceptibility%20to%20fluconazole%20for%20a%203-year%20period&rft.jtitle=Mycoses&rft.au=Comert,%20Fusun&rft.date=2007-01&rft.volume=50&rft.issue=1&rft.spage=52&rft.epage=57&rft.pages=52-57&rft.issn=0933-7407&rft.eissn=1439-0507&rft_id=info:doi/10.1111/j.1439-0507.2006.01309.x&rft_dat=%3Cproquest_cross%3E20467489%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20467489&rft_id=info:pmid/17302749&rfr_iscdi=true |